在新冠疫情期间，化脓性汗腺炎的生物治疗与银屑病的生物治疗有何不同？ - Suppr | 超能文献

Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?

作者信息

Rosi Elia, Pimpinelli Nicola, Prignano Francesca

机构信息

Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.

出版信息

J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.

DOI:10.1080/09546634.2020.1771256

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?在新冠疫情期间，化脓性汗腺炎的生物治疗与银屑病的生物治疗有何不同？

J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.

2

Biologic drugs during COVID-19 outbreak.2019冠状病毒病疫情期间的生物药物

Int J Dermatol. 2020 Oct;59(10):1293. doi: 10.1111/ijd.15088. Epub 2020 Aug 6.

3

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.2019冠状病毒病大流行期间银屑病、特应性皮炎（湿疹）、化脓性汗腺炎及痤疮/玫瑰痤疮治疗指南的更新

Dermatol Online J. 2020 Oct 15;26(10):13030/qt0j5150df.

4

Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.COVID-19 大流行期间化脓性汗腺炎患者的管理：免疫调节治疗的风险和获益。

Dermatol Ther. 2020 Nov;33(6):e14256. doi: 10.1111/dth.14256. Epub 2020 Sep 14.

5

Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.2019 冠状病毒病大流行期间用于炎症性皮肤病的生物制剂的单中心调查。

J Dermatol. 2021 Dec;48(12):1907-1912. doi: 10.1111/1346-8138.16159. Epub 2021 Sep 21.

6

Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？

Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.

7

[Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].[新冠疫情对皮肤科免疫调节和免疫抑制治疗的影响：阿根廷患者及医生的态度]

Actas Dermosifiliogr (Engl Ed). 2020 Nov;111(9):806-807. doi: 10.1016/j.ad.2020.04.004. Epub 2020 Apr 29.

8

No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.免疫调节治疗对SARS-CoV-2（新冠病毒病）疫苗效果无影响：对Epic Cosmos数据库中用于银屑病和化脓性汗腺炎患者的生物制剂和小分子抑制剂的横断面分析

J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.

9

Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.新冠疫情时代针对化脓性汗腺炎患者的生物制剂：来自意大利南部一家转诊中心的数据。

J Dermatolog Treat. 2022 Feb;33(1):592. doi: 10.1080/09546634.2020.1769828. Epub 2020 May 25.

10

Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic.化脓性汗腺炎：COVID-19大流行期间虚拟门诊护理的重要性。

J Am Acad Dermatol. 2020 Jul;83(1):e81-e82. doi: 10.1016/j.jaad.2020.04.142. Epub 2020 May 1.

引用本文的文献

1

Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.新冠疫情期间接受生物制剂治疗的银屑病和化脓性汗腺炎患者的皮肤表现

J Clin Med. 2021 Dec 13;10(24):5841. doi: 10.3390/jcm10245841.

2

Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述

Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.